SB Drug Discovery

SB Drug Discovery News

Conferences

SB Drug Discovery will be exhibiting at the following conferences in 2017.

  • Discovery on Target - Boston, MA. 26th-28th September
  • ELRIG Drug Discovery - Liverpool, UK. 3rd-4th October
  • Neuroscience - Washington, DC. 11th-15th November

Ion Channel Modulation Symposium

SB Drug Discovery is pleased to sponsor the 2017 Ion Channel Modulation Symposium, 21/22 June at Clare College, Cambridge. The symposium will bring together leading international researchers from academia and industry to share their latest advances and discuss current, cutting edge research focused on the modulation of this important class of receptors as therapeutic targets.

SB Drug Discovery - May 2017


Sustainable Biosources of Plant Natural Products

SB Drug Discovery is a member of a multidisciplinary European Commission project consortium (DISCO, http://disco-fp7.eu) which includes leading academic experts from plant genetics, molecular biology and metabolic engineering as well as industrial partners. The consortium's focus is on understanding plant biosynthetic pathways involved in the formation of high-value plant products and developing new tools for metabolic engineering and molecular breeding with the ultimate aim to generate new biosources of bioactive and industrial phytochemicals.

SB Drug Discovery - September 2016


Ion Channel Modulation Symposium

SB Drug Discovery is pleased to sponsor the 2016 Ion Channel Modulation Symposium, 16/17th June at Clare College, Cambridge. The symposium will bring together leading international researchers from academia and industry to share their latest advances and discuss current, cutting edge research focused on the modulation of this important class of receptors as therapeutic targets.

SB Drug Discovery - May 2016


SK Channels in Neuropsychiatric Research Collaboration

SB Drug Discovery's new calcium-activated potassium channel cell lines, SK1, SK2 and SK3 are to be used by scientists from the Centre for Addiction and Mental Health (CAMH) and the University of Toronto, in collaboration with Evotec, in a project aimed at identifying  novel targets for neuropsychiatric disorders.

SB Drug Discovery - May 2016